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Neuronal cell death is a pathophysiological consequence of many brain insults that trigger
epilepsy and has been implicated as a causal factor in epileptogenesis. Seizure-induced
neuronal death features excitotoxic necrosis and apoptosis-associated signaling pathways,
including activation of multiple members of the Bcl-2 gene family. The availability of mice
in which individual Bcl-2 family members have been deleted has provided the means
to determine whether they have causal roles in neuronal death and epileptogenesis
in vivo. Studies show that multiple members of the Bcl-2 family are activated following
status epilepticus and the seizure and damage phenotypes of eight different knockouts
of the Bcl-2 family have now been characterized. Loss of certain pro-apoptotic members,
including Puma, protected against seizure-induced neuronal death whereas loss of anti-
apoptotic Mcl-1 and Bcl-w enhanced hippocampal damage. Notably, loss of two putatively
pro-apoptotic members, Bak and Bmf, resulted in more seizure-damage while deletion
of Bid had no effect, indicating the role of certain Bcl-2 family proteins in epileptic
brain injury is distinct from their contributions following other stressors or in non-CNS
tissue. Notably, Puma-deficient mice develop fewer spontaneous seizures after status
epilepticus suggesting neuroprotection may preserve functional inhibition, either directly
by preserving neuronal networks or indirectly, for example by limiting reactive gliosis
and pro-inflammatory responses to neuronal death. Together, these studies support
apoptosis-associated molecular mechanisms controlling neuronal death as a component
of epileptogenesis which might be targetable to protect against seizure-damage, cognitive
deficits and mitigate the severity of syndrome following epilepsy-precipitating injuries to
the brain.
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INTRODUCTION
Epileptogenesis is the process by which a normal brain is trans-
formed into one capable of generating recurrent spontaneous
seizures (Pitkanen and Lukasiuk, 2011; Goldberg and Coulter,
2013). The process can be triggered by injuries to the brain
such as trauma, stroke, infection and acute symptomatic seizures
such as status epilepticus. Interrupting this process would offer
the possibility of preventing the development of epilepsy, a
chronic and often life-long neurologic disorder characterized by
an enduring predisposition to seizures (Chang and Lowenstein,
2003). If complete prevention is not possible, a secondary goal
would be to modify the severity of the condition, for example
resulting in fewer or less severe seizures (e.g., partial seizures
rather than generalized tonic-clonic) (Pitkanen and Lukasiuk,
2011).
Current anti-epileptic drugs (AEDs) do not appear to signifi-
cantly modify the underlying pathophysiology, with the possible
exception of levetiracetam and ethosuximide in immature models
(Loscher and Brandt, 2010; Pitkanen and Lukasiuk, 2011). This
implies that the mechanisms of ictogenesis and epileptogenesis
are not the same (Sloviter and Bumanglag, 2013). This under-
scores the need to understand the cell and molecular mechanisms
underlying epileptogenesis and then identify potentially novel
approaches and targets with which to design anti-epileptogenic
treatments.
There has been major progress in characterizing the cell and
molecular processes that occur during epileptogenesis [for review,
see Mcnamara et al. (2006); Boison (2008); Engel and Henshall
(2009); Pitkanen and Lukasiuk (2011); Vezzani et al. (2011);
Goldberg and Coulter (2013)]. Epileptogenesis is associated with
acute and delayed neuronal death, gliosis (particularly astrocytes
and microglia), changes to synaptic and circuit function (mor-
phology, channelopathies, firing properties, γ-amino butyric acid
(GABA)-ergic tone), neuroinflammation, aberrant neurogenesis
and extracellular matrix remodeling. We remain uncertain which
individual processes or combination of processes are important
and some undoubtedly reflect repair processes that are benefi-
cial (Loscher and Brandt, 2010; Sloviter, 2011). Efforts to target
epileptogenesis and prevent the subsequent emergence of epilepsy
have been largely unsuccessful to date (Loscher and Brandt, 2010;
Pitkanen and Lukasiuk, 2011).
NEURONAL DEATH AS A CONSEQUENCE OF SEIZURES AND
CAUSAL FACTOR IN EPILEPTOGENESIS
Neuron loss within the hippocampus is a common pathologic
hallmark of mesial temporal lobe epilepsy (mTLE) in humans.
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The most frequent finding is end folium sclerosis (loss of neurons
within the hilus) and loss of CA1 and CA3 pyramidal neu-
rons. Area CA2 and dentate granule neurons are usually spared,
although some neurons may also be lost from these regions
(Chang and Lowenstein, 2003; Thom, 2009). The neuron loss in
mTLE is mainly thought to be a result of an initial precipitat-
ing insult such as prolonged febrile seizures, infection, trauma or
status epilepticus. Prolonged or repeated epileptic seizures, how-
ever, may contribute to further neuron loss (Mathern et al., 2002;
Henshall and Meldrum, 2012).
Animal models of mTLE produced by repeated brief seizures
or status epilepticus are also associated with significant neu-
ron loss within the hippocampus, as well as various other
pathologic changes including gliosis, inflammation, blood brain
barrier damage and circuit reorganization. How might neu-
ronal death contribute to epileptogenesis or shape the epileptic
phenotype? Both direct and indirect mechanisms are possi-
ble. Neuron loss may cause an imbalance between excitation
and inhibition with brain networks, for example by remov-
ing inhibitory neurons or by removing excitatory neurons that
function to activate inhibitory neurons (Pitkanen, 2002; Loscher
and Brandt, 2010; Sloviter, 2011). The immediacy of epilepsy
in some models supports a direct pro-epileptogenic effect of
neuronal death. For example, spontaneous seizures are detected
with minimal delay after intense hippocampal activation via per-
forant path stimulation that destroys neurons in the dentate hilus
(Bumanglag and Sloviter, 2008). CA3-restricted lesions of the
hippocampus also produce epilepsy with minimal latency sug-
gesting neuronal death in this region is also epileptogenic (Li
et al., 2008; Mouri et al., 2008). Neuron loss is also implicated
as an epileptogenic mechanism following injury to thalamo-
cortical circuitry (Paz et al., 2010). Epilepsy has also been reported
to develop with no significant latent period following status
epilepticus-induced brain injury in humans (Mikaeloff et al.,
2006). Other supporting evidence includes the strong associ-
ation found in some studies between epileptic seizure rates
and the extent of damage to the neocortex (Kharatishvili and
Pitkanen, 2010) and hippocampus (Jimenez-Mateos et al., 2010).
Neuronal death may have pro-epileptogenic effects through indi-
rect mechanisms; reactive gliosis and inflammation accompany
neuronal damage and can promote hyperexcitability (Maroso
et al., 2010; Vezzani et al., 2011). Recent transcriptome anal-
ysis of epileptogenesis identified genes regulating apoptosis as
common to the epileptogenic process (Okamoto et al., 2010)
and mice lacking the apoptosis-regulating gene Chop exhibit
increased hippocampal damage and cognitive deficits follow-
ing status epilepticus and develop more frequent spontaneous
seizures (Engel et al., 2013).
If neuronal death is important for epileptogenesis and/or
shaping the emergent phenotype then neuroprotection should
have anti-epileptogenic effects. There are, however, relatively
few studies which have provided direct evidence. A common
problem is that drugs have been given before or during sta-
tus epilepticus and this has modified the initial precipitating
injury (Acharya et al., 2008; Loscher and Brandt, 2010; Sloviter,
2011). Excluding such studies, we are left with some exam-
ples where neuroprotection was found to be anti-epileptogenic.
Injection of rats with a neuroprotective dose of a caspase-3
inhibitor 3 h after status epilepticus strongly reduced the number
of spontaneous seizures and the proportion of rats develop-
ing epilepsy (Narkilahti et al., 2003). Neuroprotection through
seizure preconditioning is also associated with reduced sponta-
neous seizures (Jimenez-Mateos et al., 2008). Neuroprotection
also protects against cognitive deficits such as memory impair-
ment as well as behavioral changes (Loscher and Brandt,
2010).
Not all studies, however, have found a convincing link between
neuronal death and epileptogenesis. For example, glutamate
receptor antagonist and valproate treatment after status epilep-
ticus protected against cell death but did not prevent epileptoge-
nesis (Acharya et al., 2008; Loscher and Brandt, 2010). Genetic
deletion of p53 was recently shown to result in a more severe
epilepsy phenotype despite animals displaying smaller hippocam-
pal lesions after status epilepticus (Engel et al., 2010d). This may
reflect possible “neuro-overprotection” or circumstances where
loss of neurons, particular irrevocably damaged cells, aids the
tissue repair process and leads to improved functional recovery
(Andre et al., 2000; Gilby et al., 2005). Last, the role of neuronal
deathmay be less important in the developing brain where epilep-
togenesis has been reported without overt cell death (Raol et al.,
2003; Dube et al., 2006).
GENETIC TOOLS TO ADDRESS THE ROLE OF NEURONAL
DEATH IN EPILEPTOGENESIS
Pharmacological neuroprotection is rarely complete in status
epilepticus models, leaving open the question of whether full
protection, if feasible, would have a stronger anti-epileptogenic
effect. Pharmacological tools also have limitations, including the
question of when to deliver, how much, for how long and the
duration of action (Sloviter, 2011). We also lack specific drugs
to many of the pathways implicated in the control of neu-
ronal death. Genetic models enable an assessment to be made
based on the complete absence of a particular protein during
the injury. Such tools also enable us to understand the causal
roles of the genes in the signaling pathways that coordinate cell
death.
Which genes to target? Genes involved in apoptosis-associated
signaling are attractive because (1) apoptosis-associated signal-
ing is a molecular feature of seizure-induced neuronal death;
(2) extensive mouse lines have been developed to study the role
of these genes in other diseases (mainly cancer), including tar-
geting entire families; and (3) the genes are highly conserved
between mice and humans (Figure 1). The Bcl-2 family repre-
sents a large group of genes for which multiple knockout mice
exist and is the focus of the present article. In the past decade,
researchers have characterized seizures and the damage phe-
notype in mice lacking eight different members of the family.
Together, the findings reveal a select role for members of the
Bcl-2 family in seizure-induced neuronal death and evidence
that cell death controlled by Bcl-2 family proteins is functionally
important in epileptogenesis (Table 1). Reviews on the broader
topic of apoptosis and epilepsy can be found elsewhere [see
Henshall and Simon (2005); Engel and Henshall (2009); Bozzi
et al. (2011)].
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FIGURE 1 | Bcl-2 family; organization, functions, and characteristics.
Schematic shows the main Bcl-2 family proteins in humans and mice along
with the main conserved structural motifs (BH domains), grouped according
to function and depicting amino acid length and homology between
species. TM, transmembrane domain. Length refers to amino acid number
in (left side) homo sapiens and (right side) mus musculus (splice variants
not included). Homology is between human and mouse amino acid
sequences (BLAST).
Bcl-2 FAMILY PROTEINS
Bcl-2 family proteins are the gatekeepers of the intrinsic (mito-
chondrial) pathway of apoptosis (Youle and Strasser, 2008;
Hotchkiss et al., 2009; Chipuk et al., 2010). The intrinsic path-
way of apoptosis is triggered by intracellular disturbances such
as DNA damage, hypoxia, calcium overload, growth factor with-
drawal, oxidative stress and misfolded proteins (Galluzzi et al.,
2009; Tait and Green, 2010). Mitochondria are central to the con-
vergence of these signals, and in the molecular processes which
result in either restitution of cell homeostasis or execution of
cell death. Loss of mitochondrial membrane potential consti-
tutes a critical, irreversible step in cell death with subsequent
release of pro-apoptogenic proteins (cytochrome c, apoptosis
inducing factor), bioenergetic failure and downstream activa-
tion of caspase-dependent and caspase-independent cell death
(Hotchkiss et al., 2009).
The Bcl-2 family are pivotal to the initiation, integration
and execution of the intrinsic apoptosis pathway. About twenty
Bcl-2 family members are recognized in mammals, based on
sequence and function and they are typically organized into
three groups (Figure 1). The anti-apoptotic members include
Bcl-2, Bcl-xL, Bcl-w, and Mcl-1. Each member shares four
Bcl-2 homology (BH) domains and a transmembrane domain
that anchors them to intracellular membranes, particularly to
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Table 1 | Summary of effects of genetic disruption of Bcl-2 family proteins on status epilepticus-induced neuronal death and post-status
epilepsy in mice.
Gene Expected role SE model Chemoconvulsant/SE
threshold in knockout
Hippocampal
pathology in knockout
Effect on post-SE
epilepsy
References
Mcl-1a Anti-apoptotic Pilocarpine Lower threshold for
convulsions
Increased CA3 damage Not tested Mori et al., 2004
Bcl-w Anti-apoptotic i.a. KA Earlier onset of SE Increased CA3 damage Not tested Murphy et al., 2007
Bak Pro-apoptotic Systemic KA Increased seizuresb Increased CA3 damage Not tested Fannjiang et al., 2003
PTZ Same as wt
Bim Pro-apoptotic i.h. KA Same as wt Same as wt Not tested Theofilas et al., 2009
i.a. KA Same as wt Reduced CA3 damage Not tested Murphy et al., 2010
Systemic KA Same as wt Not reported Not tested Gimenez-Cassina et al., 2012
Bid Pro-apoptotic i.a. KA Same as wt Same as wt Not tested Engel et al., 2010a
Systemic KA Same as wt Not reported Not tested Gimenez-Cassina et al., 2012
Puma Pro-apoptotic i.a. KA Same as wt Reduced CA3 damage Reduced epileptic
seizures
Engel et al., 2010c
i.a. KA (high)c Same as wt Reduced CA3 damage Not tested Engel et al., 2010b
Bad Pro-apoptotic Systemic KA, PTZ Reduced seizures Not reported Not tested Gimenez-Cassina et al., 2012
Bmf Pro-apoptotic i.a. KA Same as wt Increased CA3, CA1 and
hilar damage
Increased
epileptic seizuresd
Moran et al., 2013
aStudies performed using heterozygous, not knockout mice.
bBehavioral assessment, not by EEG.
cHigher dose (1 µg) of KA was used to produce more severe SE.
d Mice displayed ∼30% more seizures although effect did not reach statistical significance.
Abbreviations: KA, kainic acid; i.a., intra-amygdala; i.h., intra-hippocampal; PTZ, pentylenetetrazole; SE, status epilepticus; SzPC, seizure preconditioning;
wt, wild-type.
mitochondria (Chipuk et al., 2010). Pro-apoptotic members are
divided into the multi-BH domain “effectors” and the BH3-
only proteins. The effectors comprise Bax and Bak. They
share BH1-3 domains and have a transmembrane domain.
Bok, a third putative member of this sub-group based on
structural similarities, appears to be less important and can-
not promote apoptosis in the absence of Bax/Bak (Echeverry
et al., 2013). Activation of Bax/Bak involves oligomerization
and pore formation in mitochondrial membranes that triggers
mitochondrial outer membrane permeabilization and release
of apoptogenic proteins (Galluzzi et al., 2009; Chipuk et al.,
2010).
BH3-only proteins are a highly heterogeneous group of struc-
turally unrelated proteins with the exception that they share
a BH3 domain in common (see Figure 1). The most accepted
model is that BH3-only proteins function either as “sensitiz-
ers,” including Bad, or “direct activators,” such as Bim and
Bid. Sensitizers bind and neutralize anti-apoptotic Bcl-2 family
proteins lowering the threshold for apoptosis, but not directly
causing mitochondrial outer membrane permeabilization or
apoptosis. Direct activators are capable of interacting with multi-
domain Bax/Bak and triggering their insertion into mitochondria
(Galluzzi et al., 2009; Chipuk et al., 2010).
SEIZURES ACTIVATE MULTIPLE Bcl-2 FAMILY PROTEINS
Multiple members of the Bcl-2 family have been found to undergo
transcriptional and/or post-translational responses following sta-
tus epilepticus in rat and mouse models. Seizures cause up-
regulation of anti-apoptotic Bcl-2 (Graham et al., 1996), Bcl-w
(Henshall et al., 2001b; Murphy et al., 2007) and Mcl-1 (Mori
et al., 2004). Seizures also upregulate and activate pro-apoptotic
Bax (Graham et al., 1996; Ananth et al., 2001; Henshall et al.,
2002; Moran et al., 2013), trigger Bid cleavage to its trun-
cated (most active) form (Henshall et al., 2001a; Engel et al.,
2010a), induce dissociation of Bad from its cytoplasmic chap-
erone 14-3-3 (Henshall et al., 2002), and upregulate at a tran-
script and/or protein level, Bim (Shinoda et al., 2004; Murphy
et al., 2010), Puma (Engel et al., 2010c), and Bmf (Moran et al.,
2013).
How do Bcl-2 family proteins regulate seizure-induced
neuronal death? Co-immunoprecipitation and mitochondrial
enrichment analysis shows pro-apoptotic Bcl-2 family proteins
functionally target anti-apoptotic members and/or cluster at
mitochondria during seizure-induced neuronal death (Henshall
et al., 2002; Shinoda et al., 2004; Engel et al., 2010a). This
is predicted to cause release of apoptogenic proteins from
mitochondria that activate downstream caspase-dependent and
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–independent cell death. The timing of the activation of pro-
apoptotic Bcl-2 family proteins (1–4 h post status epilepti-
cus) is broadly consistent with the release of apoptogenic
molecules from mitochondria; cytochrome c and apoptosis-
inducing factor are released between 1 and 4 h after sta-
tus epilepticus (Henshall et al., 2000; Murphy et al., 2007;
Engel et al., 2010a; Zhao et al., 2010). Nevertheless, there is
no direct evidence that blocking Bcl-2 family proteins alters
apoptosis signaling down-stream of mitochondria after status
epilepticus.
There is also evidence that levels of Bcl-2 family members
are altered in brain tissue from patients with pharmacoresis-
tant temporal lobe epilepsy. Analysis of hippocampus and neo-
cortex removed for the treatment of intractable seizures has
found higher levels of Bcl-2, Bcl-xL, Bcl-w, and lower levels of
Bim. The molecular repertoire appears shifted toward an anti-
apoptotic balance which may serve to resist further neuron loss in
patients experiencing frequent seizures (Henshall and Meldrum,
2012).
Several members of the Bcl-2 family have yet to be character-
ized in seizure models. These include anti-apoptotic Bcl-b and
pro-apoptotic multi-domain Bok and BH3-only proteins Bik [the
first BH3-only protein for which the mechanism of action was
specifically linked to the BH3 domain (Boyd et al., 1995)], BNip3
and Noxa, among others.
SEIZURES AND SEIZURE-INDUCED NEURONAL DEATH IN
MICE LACKING Bcl-2 FAMILY PROTEINS
Convulsive thresholds, seizure severity and/or seizure-induced
neuronal death have been assessed in knockouts of eight of the
Bcl-2 family members using status epilepticus as the trigger (see
Table 1). Chemoconvulsive thresholds and/or status epilepticus
were found to be altered in mice lacking Bak, Mcl-1, Bcl-w
and Bad, whereas loss of Bim, Bid, Puma and Bmf does not
affect evoked seizures. We do not yet understand why convul-
sant thresholds differ in some of these mice and assessment
of the neuroanatomy of these mice has in most cases ruled
out any significant structural abnormalities accounting for phe-
notypes. Possible compensatory up-/down-regulation of other
members of the Bcl-2 family have also been excluded in some,
but not all, studies. For some (e.g., Bim and Bid knockout
mice) assessments have been made by independent laboratories
and for two members of the family, Puma and Bmf, long-
term recordings have been performed to assess the impact of
the loss of the gene on spontaneous (i.e., epileptic) seizures.
Several members of the Bcl-2 family have not been tested as
yet or their assessment remains unfeasible at present because of
brain abnormalities [e.g., Bax−/− mice, (Moran et al., 2013)].
A brief chronological review of the seizure and damage pheno-
types in these mice follows and results are further summarized in
Figure 2.
Bak
Bak is predominantly expressed in neurons in the CNS
(Krajewska et al., 2002) and was the first Bcl-2 family member for
which mice lacking the gene were subjected to a functional assess-
ment in status epilepticus. Contrary to expectation, mice lacking
Bak displayed increased seizure-induced neuronal death fol-
lowing systemic kainate injection, supporting an anti-apoptotic
rather than pro-apoptotic function (Fannjiang et al., 2003)
(Table 1). Bak deficiency had no effect on pentylenetetrazol-
induced convulsions, however, and was protective in a model
of stroke (Fannjiang et al., 2003). This suggests that Bak may
switch between pro- and anti-apoptotic functions according to
the nature of the neurological insult. This may be possible because
neurons can express a Bak splice variant that serves an anti-
apoptotic function (Sun et al., 2001; Fannjiang et al., 2003). Bak
deficiency was also found to result in more severe behavioral
seizures (Fannjiang et al., 2003). Whether this relates to subtle
differences in brain development or other effects of the loss of
Bak on neuronal excitability is uncertain. It complicates, how-
ever, conclusions on whether differences in damage relate to an
altered initial insult or an effect specific to signaling pathways.
Verification of the impact of Bak loss in other models (e.g.,
pilocarpine) and direct evidence for activation in vivo may be
warranted.
Mcl-1
Mcl-1, first cloned in 1993 (Kozopas et al., 1993), is constitutively
expressed at low levels in the adult brain, including in the main
neuronal populations of the hippocampus, and Mcl-1 is strongly
up-regulated in the areas that survive status epilepticus (Mori
et al., 2004). A neuroprotective role for Mcl-1 was supported
by the finding that heterozygous mice (Mcl1+/−) (knockout
is embryonic lethal) displayed a four-fold increase in seizure-
induced neuronal death following pilocarpine-induced status
epilepticus (Mori et al., 2004). The study also found that heterozy-
gotes were more sensitive to chemoconvulsant, necessitating the
use of a lower dose of pilocarpine to produce comparable status
epilepticus (Mori et al., 2004). As with Bak-deficient mice, this
makes it somewhat difficult to conclude that effects are only due
to altered cell death signaling. Nevertheless, Mcl-1 appears to be
among the most important anti-apoptotic members of the family
in seizure models.
Bcl-w
Bcl-w was cloned in 1996 (Gibson et al., 1996) and is expressed in
many tissues, including the brain (Hamner et al., 1999; O’Reilly
et al., 2001). Protein levels of Bcl-w are bi-directionally altered in
the hippocampus after seizures (Henshall et al., 2001b; Murphy
et al., 2007). In damaged subfields after status epilepticus, Bcl-w
appears to be targeted by Bim and becomes integrated, possibly
inactivated, in the mitochondrial compartment (Shinoda et al.,
2004; Murphy et al., 2007). In contrast, Bcl-w is up-regulated
following brief electroshock seizures, a model of epileptic toler-
ance (Murphy et al., 2007). Hippocampal damage is significantly
increased in Bcl-w-deficient mice following status epilepticus
(Murphy et al., 2007). The mice also display a shorter time period
between injection of the chemoconvulsant and their first paroxys-
mal seizure discharge. As a result, Bcl-w deficient mice experience
a longer period of status epilepticus during monitoring (Murphy
et al., 2007). A statistical analysis of the relationship between
seizure duration and damage showed this could not account
for all the additional damage (Murphy et al., 2007). Thus, the
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FIGURE 2 | Bcl-2 family-regulated pathway and phenotypes in Bcl-2
knockout mice after status epilepticus. Cartoon depicts the relationship
between the activated Bcl-2 family proteins after status epilepticus, the
signaling pathways they drive toward cell death, and possible consequences
of such cell death on epileptogenesis. Multiple BH3-only proteins are
activated by epileptogenic insults which may promote mitochondrial
dysfunction via Bax or other mechanisms, a step that can be blocked by
anti-apoptotic members of the Bcl-2 family. The cell death controlled by this
pathway may promote tissue repair or drive epileptogenesis via disruption of
neuronal networks. The phenotype of Bcl-2 family protein knockout mice is
indicted in the boxes linked by a stalk. For each, the key shows how deletion
of the gene impacts convulsive thresholds (e.g., to kainate), hippocampal
injury after status epilepticus or emergent spontaneous seizures. Not
represented: The figure does not include other intracellular compartments in
which Bcl-2 family proteins are commonly found such as the endoplasmic
reticulum. SE, status epilepticus.
exacerbated hippocampal injury in Bcl-w-deficient mice is at least
partly the result of losing the neuroprotective properties of the
protein. As withMcl-1 and Bak, we do not knowwhy these knock-
out mice display altered responses to chemoconvulsants but it is
assumed to relate to subtle effects of gene deficiency on brain
development or non-cell death related functions of the proteins
that impact on excitability.
Bim
Bim was the first of the BH3-only proteins studied for a causal
role in seizure-induced neuronal death. Mice lacking Bim dis-
play select abnormalities of apoptosis control (Bouillet et al.,
1999) but the brain appears normal (Murphy et al., 2010). Bim
is upregulated in a Foxo- or JNK-dependent manner following
status epilepticus, and has been shown to co-immunoprecipitate
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with anti-apoptotic Bcl-2 family proteins, suggesting it is active
(Shinoda et al., 2004; Murphy et al., 2010). Three studies have
investigated the effect of loss of Bim, all in kainate models. In
the first, kainate was directly injected into the hippocampus and
in that study mice lacking Bim showed no difference in seizures
or neuronal death (Theofilas et al., 2009). In contrast, a sig-
nificant reduction in hippocampal damage was found in mice
lacking Bim in which seizures were triggered by intra-amygdala
kainate, although cortical injury was not affected (Murphy
et al., 2010). Again, seizures were normal in Bim−/− mice. The
authors suggested that deficiency in Bim protects only those
regions in which Bim was normally induced by seizures (Murphy
et al., 2010). Other data support causal roles for Bim in exci-
totoxic neuronal death (Concannon et al., 2010). A third study
that used systemic kainate to trigger seizures in Bim-deficient
mice, in this case forebrain-specific knockouts, also found the
mice underwent normal seizures (Gimenez-Cassina et al., 2012).
Thus, loss of Bim has no effect on seizures although has a
model- and brain region-specific contribution to seizure-induced
neuronal death.
Puma
Puma (Bbc3) is present at very low levels in the normal adult
brain but undergoes rapid up-regulation after status epilepticus,
driven by p53 (Engel et al., 2010c). Seizure-induced neuronal
death was found to be strongly reduced in mice lacking Puma
(Engel et al., 2010c). Lack of Puma also protected in a model of
more severe status epilepticus, suggesting that Puma deficiency
protects against necrosis (Engel et al., 2010b). The development of
spontaneous seizures was also investigated in Puma-deficient and
Puma-expressing mice subject to status epilepticus. Remarkably,
mice lacking Puma had over 60% less epileptic seizures during
the two week recordings. Also, only 63% of these mice devel-
oped any spontaneous seizures (vs. 89% of the heterozygous
animals used as seizure-controls). When epileptic seizures did
occur, they were of similar severity and duration (Engel et al.,
2010c). The mechanism of this anti-epileptic effect is uncer-
tain. The reduced neuronal death may have resulted in dimin-
ished gliosis and reduced inflammation. Neuroprotection may
also have preserved some functional inhibition although elec-
trophysiological studies were not performed and the type of
protected neurons (e.g., glutamatergic or GABAergic) remain
unidentified.
Bid
Bid is another member of the subgroup of potently pro-apoptotic
BH3-only proteins that is robustly expressed in the adult brain,
including in hippocampal neurons (Krajewska et al., 2002).
Previous work had shown the loss of Bid to protect against focal
cerebral ischemia in vivo and excitotoxicity in vitro (Plesnila et al.,
2001; Yin et al., 2002); the expectation was that Bid loss would
also prevent seizure-induced neuronal death. Although Bid was
activated by status epilepticus, seizure-induced neuronal death
in Bid−/− mice was similar to wild-type animals (Engel et al.,
2010a). In this and another recent study, seizures were not dif-
ferent, indicating that Bid probably does not have a critical role in
neurodevelopment or neurophysiological functions (Engel et al.,
2010a; Gimenez-Cassina et al., 2012). Thus, in contrast to estab-
lished pro-apoptotic roles in ischemic brain injury in vivo, loss of
Bid does not affect seizure-induced neuronal death. This suggests
the contribution of individual BH3-only proteins is dependent
on the brain insult which may be because of differences in the
nature of the molecular stress and how this interacts with the
prevailing expression of the protein at the time of the insult
(Engel et al., 2011).
Bad
While hippocampal damage after status epilepticus in mice
lacking Bad has not been reported, convulsive thresholds have
been investigated. Mice lacking Bad display significantly reduced
seizure severity in response to kainate and other chemoconvul-
sants (Gimenez-Cassina et al., 2012). No other mouse lacking a
BH3-only protein has been found to have such a phenotype. The
cause of the anticonvulsant effect of Bad deficiency may relate to
reduced mitochondrial use of glucose and a shift to use of ketone
bodies; possibly the same mechanism that underlies the anti-
epileptic effect of the ketogenic diet (Danial et al., 2013) (see also
below).
Bmf
The most recently studied Bcl-2 family protein in seizure-induced
neuronal death is Bmf. Transcript levels of Bmf are increased
rapidly following status epilepticus in mice in a AMP kinase
dependent manner, although the paucity of specific antibodies
has prevented an assessment of where the protein is within the
hippocampus and whether this is affected by seizures (Moran
et al., 2013). Bmf-deficient mice display normal neuroanatomy
and undergo normal seizures in the intra-amygdala kainatemodel
(Moran et al., 2013). Remarkably, however, mice lacking Bmf
displayed significantly more, not less, seizure-induced neuronal
death than wild-types. Increased damage was mainly found in
the CA3 subfield but was also evident in CA1 and the hilus and
even in the contralateral hippocampus, an area normally spared
in this model (Moran et al., 2013). This is the first example of a
BH3-only protein apparently protecting against seizure-induced
neuronal death. Nevertheless, the mechanism of this protection is
unknown. Long-term EEG recordings in Bmf−/− mice after sta-
tus epilepticus found ∼30% higher rate of spontaneous seizures,
suggesting exacerbated hippocampal damage may worsen the
form of developed epilepsy (Moran et al., 2013). Notably, the
severity of individual seizures was not different in the Bmf−/−
animals supporting findings with Puma-deficient mice that mod-
ulating neuronal cell death affects the occurrence/threshold of
the seizures but not the severity of the seizures once they occur
(Engel et al., 2010c).
ARE THERE COMPENSATORY RESPONSES IN KNOCKOUT
MICE THAT DO NOT DISPLAY A PHENOTYPE?
It might be possible that compensatory responses in knock-
out mice rather than functional redundancy explain the lack
of seizure phenotype in some models. This may be the case
for Bid, where increased Bim is observed (Engel et al., 2010a),
although this is not direct evidence of compensation. In other
studies, compensatory up- or down-regulation of other Bcl-2
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family proteins has not been found (Fannjiang et al., 2003; Moran
et al., 2013) although the same level of a related protein may take
over functions, especially in a group of proteins that are highly
dependent on subcellular distribution, as is the case with the Bcl-2
family.
CONSTITUTIVE AND NON-CANONICAL FUNCTIONS OF Bcl-2
FAMILY PROTEINS IN THE BRAIN
The presence of quite high levels of several pro-apoptotic Bcl-
2 family proteins in the normal adult mammalian brain is at
odds with the need for neurons to survive for many years or
decades; possessing high levels of proteins whose only role is to
kill cells is both energy-expensive and risky. Moreover, several
non-Bcl-2 family-related components of the apoptotic machin-
ery are down-regulated in the adult brain including the apoptotic
protease activating factor-1 (Apaf-1) and caspase-3 (Yakovlev
et al., 2001). We now know that particular Bcl-2 family pro-
teins have non-canonical roles, reviews of which can be found
elsewhere (Lamb and Hardwick, 2010; Hardwick et al., 2012).
In some cases this involves a switch to anti-apoptotic rather
than pro-apoptotic function, as for Bak (Fannjiang et al., 2003)
and perhaps Bmf (Moran et al., 2013). For others, however,
Bcl-2 family proteins serve completely different functions in
the normal brain, although remain capable of being co-opted
to regulate cell death when called upon (e.g. after a severe
stressor).
Bad has previously been implicated in the control of glycolysis
in non-neuronal cells (Danial et al., 2003). Recent work showed
that Bad is also involved in metabolism of glucose in neurons
and glia (astrocytes) (Gimenez-Cassina et al., 2012). Loss of Bad
resulted in a switch to ketone-based metabolism in neurons. This
may phenocopy the ketogenic diet and the study reported that
mice lacking Bad displayed strongly reduced seizure susceptibil-
ity to kainate and pentylenetetrazole (Gimenez-Cassina et al.,
2012).
Bcl-xl contributes to mitochondrial outer membrane conduc-
tance which in turn may enhance synaptic transmission (Jonas
et al., 2003; Chen et al., 2011). Bcl-xL also potentiates ATP
production in neurons in the resting and active state, which
appears to result from a more efficient use of oxygen in ATP pro-
duction and effects on the F1F0 ATPase (Alavian et al., 2011).
Whether these effects are independent of the canonical role of
Bcl-xL in inhibiting apoptosis is unclear. Bcl-xL as well as sev-
eral other members of the Bcl-2 family are linked to the con-
trol of intracellular calcium homeostasis (Hetz and Glimcher,
2008).
A seizure phenotype was also found in Bcl-w-deficient mice.
Although the mechanism is not understood, electrophysiology
and binding studies showed that Bcl-w can augment GABA-
evoked currents in neurons (Murphy et al., 2007).
These emerging, non-cannonical functions of Bcl-2 family
proteins in the brain are an exciting focus of research that may
yield mechanisms relevant to epileptogenesis independent of their
traditional roles in controlling cell death. Modulating certain
Bcl-2 family proteins that have direct effects on excitability is
an alternative tactic that may complement the neuroprotective
therapeutic opportunities of targeting this gene family.
SUMMARY AND FUTURE DIRECTIONS
Neuronal loss is a potential consequence of prolonged or
repeated brief seizures and may contribute to epileptogene-
sis. The availability of Bcl-2 family knockout mice has enabled
epilepsy researchers to learn about the functional contribu-
tions of this gene family to seizure-induced neuronal death.
Eight members of this family have been assessed in vivo
using genetic models, representing one of the most compre-
hensive analyses of any single gene family in the epilepsy
field. The studies have significantly expanded our understand-
ing of the influence of apoptosis-associated signaling pathways
in epileptogenesis, revealing effects on convulsant thresholds and
neuronal death. For two members, altered spontaneous seizures
were also reported in mice lacking a Bcl-2 family member
supporting neuronal death controlled by these genes as hav-
ing direct or indirect effects on functional inhibition in the
brain.
What are some of the next challenges? Studies are needed to
test network function and explore the underlying direct and indi-
rect mechanisms by which modulation of Bcl-2 family proteins
influences cell death and excitability. Bcl-2 family proteins have
important non-cell death functions in neurons, some of which
are directly relevant to the excitability of the brain and thus may
be novel treatment targets in epilepsy. We know relatively little
about which hippocampal cell type(s) make these proteins. There
is an assumption that all effects are neuronally-mediated but this
needs to be established. All work to date has used knockouts
and there is a need to investigate whether transgenic overexpres-
sion of an anti-apoptotic Bcl-2 family protein such as Mcl-1 can
reduce seizure damage and/or have an anti-epileptogenic effect.
There remain important members of the family for which we
have little or no data on their influence on seizures and dam-
age in a genetic model in vivo, including Bcl-xL. The possibility
that some Bcl-2 family proteins can compensate for others could
be tested using double (or even triple) knockout mice, which are
now available (Ren et al., 2010). This may be particularly apt
for Bid where the absence of a damage phenotype in the knock-
out was unexpected. Another key experiment is to prove that
seizure-induced cell death is really Bax-dependent in vivo. Bax-
deficient mice display brain abnormalities that are presumably a
result of deficiencies in developmental cell death (Moran et al.,
2013), necessitating the use of conditional Bax knockout mice.
Conditional knockouts or transgenic mice would also provide
a means to test whether the pro/anti-convulsive seizure thresh-
olds in certain Bcl-2 family knockouts (see Table 1) are simply
an effect of the loss of the gene during brain development or
instead represent an effect relating to neurophysiologic functions
of the protein in the adult brain. Finally, can the knowledge be
applied therapeutically? We know the transcriptional and post-
transcriptional control mechanisms for many of the Bcl-2 family
proteins and these provide potential drug targets. The availability
of BH3mimetics, developed for use in cancer, offer tools to probe
the contribution of Bcl-2 family proteins in seizure models but we
await small molecules that enhance or mimic the actions of anti-
apoptotic members of the Bcl-2 family that might be put to use to
protect the brain against injury caused by status epilepticus and,
perhaps, epileptogenesis.
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